ES2714999T3 - Terapia de combinación que usa inmunoglobulina e inhibidor de C1 - Google Patents

Terapia de combinación que usa inmunoglobulina e inhibidor de C1 Download PDF

Info

Publication number
ES2714999T3
ES2714999T3 ES12761739T ES12761739T ES2714999T3 ES 2714999 T3 ES2714999 T3 ES 2714999T3 ES 12761739 T ES12761739 T ES 12761739T ES 12761739 T ES12761739 T ES 12761739T ES 2714999 T3 ES2714999 T3 ES 2714999T3
Authority
ES
Spain
Prior art keywords
inh
ivig
administered
immunoglobulin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12761739T
Other languages
English (en)
Spanish (es)
Inventor
Milan Basta
Xinzhi Chen
Mark Mattson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
United States Department of Health and Human Services
Original Assignee
CSL Behring GmbH Deutschland
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland, United States Department of Health and Human Services filed Critical CSL Behring GmbH Deutschland
Application granted granted Critical
Publication of ES2714999T3 publication Critical patent/ES2714999T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES12761739T 2011-09-24 2012-09-21 Terapia de combinación que usa inmunoglobulina e inhibidor de C1 Active ES2714999T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538832P 2011-09-24 2011-09-24
PCT/EP2012/068643 WO2013041677A1 (en) 2011-09-24 2012-09-21 Combination therapy using immunoglobulin and c1-inhibitor

Publications (1)

Publication Number Publication Date
ES2714999T3 true ES2714999T3 (es) 2019-05-31

Family

ID=46881067

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12761739T Active ES2714999T3 (es) 2011-09-24 2012-09-21 Terapia de combinación que usa inmunoglobulina e inhibidor de C1

Country Status (9)

Country Link
US (1) US10471142B2 (enExample)
EP (1) EP2758076B1 (enExample)
JP (1) JP6190368B2 (enExample)
KR (1) KR101956585B1 (enExample)
CN (1) CN104010656B (enExample)
AU (1) AU2012311483B2 (enExample)
DK (1) DK2758076T3 (enExample)
ES (1) ES2714999T3 (enExample)
WO (1) WO2013041677A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103415301A (zh) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
DK2961422T3 (en) * 2013-02-28 2017-01-16 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
ME02865B (me) 2013-03-15 2018-04-20 Shire Viropharma Inc C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
ME03318B (me) 2013-11-22 2019-10-20 Shire Viropharma Inc Postupci lečenja odbacivanja posredovanog antitelima pacijenata sa transplatiranim organom sa inhibitorom c1-esteraze
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
WO2016131958A1 (en) * 2015-02-20 2016-08-25 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
CN109562149A (zh) 2016-08-05 2019-04-02 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
WO2022251654A1 (en) * 2021-05-28 2022-12-01 West Virginia University Board of Governors on behalf of West Virginia University Mitoneet ligands for use in protection from tissue ischemic reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009158A (en) * 1934-08-01 1935-07-23 Ophthalmological Foundation In Ophthalmic ergograph
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4227762A1 (de) 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
WO2001019392A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8071532B2 (en) * 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
EP2233499A1 (en) * 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

Also Published As

Publication number Publication date
KR20140075753A (ko) 2014-06-19
AU2012311483B2 (en) 2016-03-10
US20140234293A1 (en) 2014-08-21
WO2013041677A1 (en) 2013-03-28
HK1200334A1 (en) 2015-08-07
DK2758076T3 (en) 2019-04-01
KR101956585B1 (ko) 2019-03-11
US10471142B2 (en) 2019-11-12
CA2848510A1 (en) 2013-03-28
JP2014526541A (ja) 2014-10-06
AU2012311483A1 (en) 2013-05-16
CN104010656A (zh) 2014-08-27
EP2758076B1 (en) 2018-12-12
JP6190368B2 (ja) 2017-08-30
EP2758076A1 (en) 2014-07-30
CN104010656B (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
US10471142B2 (en) Combination therapy using immunoglobulin and C1-Inhibitor
ES2407429T3 (es) Vacuna terapéurica
ES2245028T3 (es) Uso de lactoferrina en el tratamiento de trastornos inducidos por alergenos.
AU2005211890B2 (en) Highly concentrated liquid formulations of anti-EGFR antibodies
TWI831106B (zh) 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
ES2745041T3 (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios
ES2587863T3 (es) Uso de un inhibidor de C1 para el tratamiento de un edema secundario del sistema nervioso central
Luyten et al. Yellow nail syndrome and onychomycosis: experience with itraconazole pulse therapy combined with vitamin E
US20160060324A1 (en) Methods and Compositions for Treating Bleeding Disorders
ES2965454T3 (es) Protocolo mejorado para el tratamiento de la nefritis lúpica
ES2216516T3 (es) Inmunorregulador.
JP7351835B2 (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
MXPA04007311A (es) Tratamiento de ms con suero de cabra.
JP7246094B2 (ja) 活性調節剤
JP2010535199A (ja) コハク酸を含む鼻腔内医薬品組成物
JP6288815B2 (ja) 肺炎等を治療するための医薬組成物
CA2848510C (en) Combination therapy using immunoglobulin and c1-inhibitor
EP3137094A1 (en) Treatment and prevention of alzheimer's disease (ad)
ES2651537T3 (es) Tratamiento y prevención de la enfermedad de Alzheimer (AD)
WO2016131958A1 (en) Pharmaceutical formulations of c1 esterase inhibitor
HK1200334B (en) Combination therapy using immunoglobulin and c1-inhibitor
CN110882240B (zh) 作为急性缺血性中风的治疗剂的多酚衍生物化合物6-cepn
CN101410138A (zh) 作为药用产品的对切昆贡亚热特异的免疫球蛋白的浓缩物
RU2473364C2 (ru) Способ лечения клещевого энцефалита
Somaratne et al. A child with acquired haemophilia